- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg, Placebo only
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 24
- States / cities
- Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2401–2424
of 5,528
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Oglemilast, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
- Conditions
- Autism Spectrum Disorders
- Interventions
- Citalopram, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 10 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- Emixustat HCl Tablet, Placebo Tablet
- Drug · Other
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Hepatitis B
- Interventions
- Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hypertension
- Interventions
- Ambrisentan 5 mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Dallas, Texas
- Conditions
- Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Macitentan, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 24
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- Restless Legs Syndrome
- Interventions
- GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
- Interventions
- Cinacalcet, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
- Conditions
- Hirschsprung Disease
- Interventions
- VSL#3, Placebo
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 1 Month to 12 Months
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Buffalo, New York
- Conditions
- EPP, XLP
- Interventions
- Placebo, MT-7117 Low Dose, MT-7117 High Dose
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Huntington Beach, California • Miami, Florida • Brighton, Massachusetts + 7 more
- Conditions
- Lymphoma
- Interventions
- Ibrutinib, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Greenbrae, California • La Jolla, California + 41 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- Placebo, SU011248
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 27
- States / cities
- Duarte, California • Los Angeles, California • Pasadena, California + 20 more
- Conditions
- Uterine Fibroids
- Interventions
- Elagolix, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
- Conditions
- Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
- Interventions
- mometasone furoate, placebo
- Drug · Other
- Lead sponsor
- North Central Cancer Treatment Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 189
- States / cities
- Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
- Conditions
- Alzheimer's Disease
- Interventions
- ST101, Placebo
- Drug
- Lead sponsor
- Sonexa Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Stiolto Respimat, Placebo Respimat
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- HCC
- Interventions
- Sorafenib, VT-122 (propranolol plus etodolac), Placebo
- Drug
- Lead sponsor
- Vicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 10
- States / cities
- Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more
- Conditions
- Erectile Dysfunction, Sexual Dysfunction, Physiological
- Interventions
- Levitra (Vardenafil, BAY38-9456), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 11
- States / cities
- Laguna Hills, California • Jeffersonville, Indiana • Des Moines, Iowa + 8 more
- Conditions
- Atrial Fibrillation
- Interventions
- Colchicine 0.6 mg, Placebo
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
- Drug · Other
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BMS-986020, Placebo matching with BMS-986020
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more